Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.57 |
| ▸ | CTSS | P25774 | 3/20 | 0.57 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15488335 | 1.00 | CTSK (0.57) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL15488043 | 1.00 | CTSK (0.57) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL21767271 | 1.00 | CTSK (0.57) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL8466501 | 0.88 | CTSS (0.59) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL8466502 | 0.88 | CTSS (0.59) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL3730087 | 0.86 | CTSK (0.58) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL3730085 | 0.86 | CTSK (0.58) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL28469162 | 0.86 | CTSK (0.58) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL17011363 | 0.86 | CTSK (0.54) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL3180769 | 0.86 | CTSK (0.54) | CTSKCTSSPSENENCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200199097-A1 | POMALIDOMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR | NANJING NORATECH PHARMACEUTICALS CO., LTD (CN) | 2020-06-25 | — | — | US | disclosed |
| US-20190352300-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. (US) | 2019-11-21 | — | — | US | disclosed |
| US-10316038-B2 | Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer | ACLARIS THERAPEUTICS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180208594-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2018-07-26 | — | — | US | disclosed |
| US-20180208594-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2018-07-26 | — | — | US | disclosed |
| CN-103626765-B | Substituted azaindole compounds and salt, compositions and purposes | 广东东阳光药业有限公司 | 2016-08-10 | — | — | CN | disclosed |
| US-7674912-B2 | Pro-drugs of N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2010-03-09 | — | — | US | disclosed |
| US-20060264485-A1 | Pro-drugs of N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316038-B2 | Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer | ITK, PDXK, WEE1 | CTSK 143/4885CTSS 2188/4885PSENEN 3318/4885 |
| US-20190352300-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, PDXK, WEE1 | CTSK 143/4885CTSS 2188/4885PSENEN 3318/4885 |
| US-20200199097-A1 | POMALIDOMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR | WEE2, WEE1, HASPIN | CTSK 3193/4885CTSS 2529/4885PSENEN 4010/4885 |
| US-20060264485-A1 | Pro-drugs of N-thiazol-2-yl-benzamide derivatives | ADORA2A, ADORA2B, ADORA1 | CTSK 2500/4885CTSS 2402/4885PSENEN 515/4885 |
| US-20180208594-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, PDXK, WEE1 | CTSK 143/4885CTSS 2188/4885PSENEN 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.